Technology | November 02, 2009

GE Spotlights PET/CT, New Image-Guided Ultrasound System at ASTRO

November 2, 2009 – GE Healthcare is spotlighting its Discovery PET/CT 600, unveiling the new LOGIQ P6 Ultrasound for image-guided radiation therapy, and more technology that demonstrates the potential connections across the cancer care continuum at the American Society for Radiation Oncology (ASTRO) meeting in Chicago, Ill., Nov. 1-5, 2009.

“Oncology care is about making connections,” said Paul Anderson, General Manager of Oncology for GE Healthcare. “It’s about making the connection between the disease, the treatment, the patients and the multi-disciplinary clinical team.”

Advances in radiotherapy treatments have required parallel advancements in imaging, providing oncology specialists with imaging technology that moves from basic qualitative information to deliver high-level quantitative patient data. These refinements have allowed oncologists to better target the therapies by connecting all components that are key to personalized patient cancer treatment. The multi-modality oncology suite connects care from pathways to simulate therapy delivery, to gauging the response to actual treatment, to monitoring its efficacy.

GE’s booth at ASTRO will spotlight the connections between disease and treatment, as well as between clinician and patient. At the same time, broader clinical connections that link patient information, department workflow and oncology management will be demonstrated. Products whose spotlighted advances in cancer diagnostics and care include:
• LightSpeed RT16
A wide bore CT system specifically designed to meet the needs of a Radiation Oncology department for CT simulation. It delivers excellent image quality and the power to support 4D studies, while allowing extra space in the bore for accurate patient positioning. The system’s capabilities, combined with radiation oncology software applications, help enhance image accuracy for radiation therapy planning.
· Signa™ MR Oncology Package
Enhances magnetic resonance imaging for radiation therapy planning and is compatible with the most widely used GE MRI systems. The package consists of a detachable flat-surface patient table with indexed edges, flexible surface coils for high-resolution imaging and treatment positioning aids.
• Discovery PET/CT 600
Features high sensitivity with the next generation of MotionFree technology to deliver a high degree of clinical confidence when simulating therapy.

• LOGIQ® P6 Ultrasound
A small, portable package that handles a broad range of applications, from abdominal to small parts imaging, with exceptional 4-D clarity and definition. LOGIQ P6 supports brachytherapy procedures with report package and compatibility with most stepper device manufacturers.

• Centricity PACS-IW Oncology Workflow

Integrates the web-based design and intuitive interface of PACS-IW with automated PET/CT fusion, analysis and multi-modality reading tools. This integration of oncology image interpretation and review into the multi-modality world of PACS enables clinicians to have easy access to the full set of available clinical information.

Oncology workstation

GE Healthcare will also showcase its powerful oncology workstation that helps reduce time spent on 4D planning and complex multi-modality cases, while streamlining radiation oncology workflow. As a continuous effort to maintain seamless interoperability, GE joined the IHE-RO task force formed by ASTRO for promoting interoperability between vendors. GE Healthcare successfully passed the interoperability testing at the annual IHE-RO connectathon and will continue to work together with IHE-RO to advance these efforts.
• AdvantageSim™ MD

A fast, easy and simple virtual simulation tool that helps streamline workflow from scan to plan. It helps reduce time spent on tasks and helps improve accuracy.

• Advantage 4D

A fast, powerful motion assessment tool that helps make 4D planning routine across the clinical practice.

• Advantage Fusion

Enhances tumor definition by automatically co registering CT, PET and MR images.

“We have a long, diverse relationship with the radiation oncology community,” said Anderson. “GE Healthcare has forged their own connection to this medical specialty by providing advanced tools and solutions that drive productivity and enhance today’s treatment delivery technologies.

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Overlay Init